Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 7/20 | 0.41 |
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643584 | 0.75 | TYR (0.36) | PIN1 | |
| Hydrochloric Acid SCHEMBL2652082 | 0.69 | PANK3 (0.57) | — | |
| SCHEMBL31272960 | 0.69 | CYP1A2 (0.40) | CYP1A2ECE1MMEAGTR2 | |
| SCHEMBL1249267 | 0.68 | TYR (0.48) | CYP1A2 | |
| SCHEMBL7430133 | 0.67 | KDM4E (0.47) | CYP1A2 | |
| SCHEMBL8909195 | 0.67 | DRD1 (0.42) | — | |
| SCHEMBL360413 | 0.65 | ADH5 (0.67) | — | |
| SCHEMBL11687674 | 0.65 | ALDH1A1 (0.42) | CYP1A2 | |
| SCHEMBL12799249 | 0.65 | NAALAD2 (0.49) | CYP1A2ECE1MMEAGTR2PIN1 | |
| SCHEMBL26926551 | 0.65 | CYP1A2 (0.68) | CYP1A2ECE1MMEAGTR2PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYP1A2 1974/4885ECE1 1089/4885MME 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.